Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance

Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance in Pre-Abdominoplasty Surgical Excisions and Post-Operative Scar Appearance In Subjects Undergoing Abdominoplasty

Multicenter, double-blind study comparing SLI-F06 to vehicle formulation buffer for the improvement in scar appearance and wound strength in routine surgical excisions, as well as post-operative abdominoplasty scar appearance.

Study Overview

• Status: Completed
• Conditions: Scars
• Intervention / Treatment: Drug: SLI-F06; Drug: Formulation buffer

Detailed Description

The study is divided into 2 parts where Part A is a Phase I safety/proof of concept study of small scars pre-abdominoplasty, and Part B is a Phase IIa study of post-abdominoplasty scars.

In Part A of the study, subjects will have their abdominoplasty site mapped to accommodate a series of excisions depending on pannus size. All excisions to be treated with SLI-F06 will be on one side of the mapped area (i.e., left side or right side) and vehicle treated excisions will be on the other side of the mapped area. At time of abdominoplasty the excision site will be harvested and processed.

In Part B of the study, subjects who complete Part A will be randomly assigned to receive injections of SLI-F06 along one half (left or right) of the abdominoplasty incision and control injections along the other half. The subject will undergo routine wound care and will attend study follow-up visits following abdominoplasty. The entire incision will be treated post-operatively in precisely the same manner.

Duration of study-approximately 26 months.

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60611-2950
      • Site 1
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Site 2
  • Pennsylvania
    • Bala-Cynwyd, Pennsylvania, United States, 19004
      • Site 3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative urine pregnancy test (UPT) at Visit 1a and 1b and practice a reliable method of contraception throughout the study.
2. Seeking or scheduled for standard elective abdominoplasty.
3. Willing to undergo directed excisions and follow-up prior to abdominoplasty and to undergo all follow-up visits after abdominoplasty.
4. Willing to undergo directed excisions under local anesthetic
5. Be able to follow study instructions and likely to complete all required visits.
6. Sign the Institutional Review Board (IRB)-approved Informed Consent Form (ICF), which includes the Photographic Release Form and HIPAA, prior to any study-related procedures being performed.

Exclusion Criteria:

1. Female subjects that are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.
2. Known hypersensitivity or previous allergic reaction to any constituent of the investigational product (IP).
3. History of diabetes mellitus or a Hemoglobin (HgB) A1C greater than 5.7 percent.
4. Morbid obesity (i.e., BMI >40).
5. History of prior abdominal surgery.
6. History of abdominal liposuction, cryolipolysis, focused ultrasound or other fat reduction procedures in or near the anterior abdomen within 12 months of baseline.
7. History of poor or delayed wound healing such as a prior wound dehiscence, chronic wound or leg ulcer.
8. History of or evidence of a genetic collagen disorder such as Ehlers-Danlos syndrome.
9. Operating Physician unable to design an abdominoplasty incision area of at least 25 cm wide by 12 cm tall at the center of the fusiform.
10. The presence of any abnormality of the skin within the area of the proposed abdominoplasty that, in the opinion of the Principal Investigator (PI), could interfere with the excision process or grading of the resultant surgical scar.
11. Use of any restricted concomitant medications/procedures or tobacco/inhaled nicotine products within a restricted time period.
12. Allergy to or intolerance of local anesthetics.
13. Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with interpretation of study results or compliance of the subject and, in the opinion of the PI, would make the subject inappropriate for study entry.
14. Any personal, familial, employment or financial situation that could impede the subject's ability to attend all study visits and successfully complete the entire clinical study.
15. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
16. Exposure to any other investigational drug/device within 30 days prior to study entry.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: SLI-F06; Drug Product under investigation	Drug: SLI-F06; Active treatment; Other Names: F06-C40
Placebo Comparator: Formulation Buffer; Placebo	Drug: Formulation buffer; Placebo treatment; Other Names: Placebo, vehicle

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient and Observer Scar Assessment Scale (POSAS) - PI Assessment	POSAS is an established scale for assessing scar by both the patient and the observer. The overall opinion of the scar is reported on a scale of 1-10, with 1 being normal skin and 10 being the worst scar. Comparisons between treatment groups for efficacy analyses are based on 95% confidence intervals (CI) calculated using mixed models with treatment group as a fixed effect and subject as a random effect to account for multiple observations (i.e., scars) within subject.	Post-excision at Month 3
Patient and Observer Scar Assessment Scale (POSAS) - PI Assessment	POSAS is an established scale for assessing scar by both the patient and the observer. The overall opinion of the scar is reported on a scale of 1-10, with 1 being normal skin and 10 being the worst scar. Comparisons between treatment groups for efficacy analyses are based on 95% confidence intervals (CI) calculated using mixed models with treatment group as a fixed effect and subject as a random effect to account for multiple observations (i.e., scars) within subject.	Post-abdominoplasty at Month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient and Observer Scar Assessment Scale (POSAS) - Subject Assessment	POSAS is an established scale for assessing scar by both the patient and the observer. The patient scale asks questions about pain, itching, color, stiffness, thickness, irregularity, and overall opinion of the scar on a scale of 1-10, with 1 being none or normal and 10 being very much or very different.	Post-excision at Day 8, and Months 1, 2, and 3, then post-abdominoplasty at Months 1, 2, 3, 6, 9 and 12
Scar Tensile Strength	Excised scar tissue will be mechanically tested to measure scar tensile strength	Post-excision at Months 1, 2, and 3
Scar Histology	Excised scar tissue will be assessed under a microscope.	Post-excision at Months 1, 2, and 3. Staining with H&E staining, Masson's trichrome, methenamine silver and immunofluorescence.
Patient and Observer Scar Assessment Scale (POSAS) - PI Assessment	POSAS is an established scale for assessing scar by both the patient and the observer. The observer scale consists of 7 parameters (vascularity, pigmentation, thickness, relief, pliability and surface area) and the overall opinion of the scar on a scale of 1-10, with 1 being normal skin and 10 being the worst scar.	Post-excision at Day 8, and Months 1 and 2, then post-abdominoplasty at Months 1, 2, 3, 6, and 9

Collaborators and Investigators

• Sponsor: Scarless Laboratories, Inc.
• Collaborators: ethica Clinical Research Inc.
• Investigators: Principal Investigator: Robert D. Galiano, MD, Northwestern University

Study record dates

Study Major Dates

• Study Start (Actual): March 3, 2019
• Primary Completion (Actual): May 18, 2021
• Study Completion (Actual): May 18, 2021

Study Registration Dates

• First Submitted: March 5, 2019
• First Submitted That Met QC Criteria: March 16, 2019
• First Posted (Actual): March 19, 2019

Study Record Updates

• Last Update Posted (Actual): April 18, 2023
• Last Update Submitted That Met QC Criteria: March 24, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Fibrosis; Cicatrix
• Other Study ID Numbers: SLI-C40-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No